Your Pathology Report: Decoding the Microscope
At a Glance
An intraductal breast papillomatosis pathology report shows whether the papilloma is benign, contains atypical cells such as ADH, or meets criteria for DCIS. Myoepithelial markers support interpretation but cannot be used alone to rule out cancer.
When you receive a pathology report for intraductal breast papillomatosis, you are looking at a translation of what a doctor (the pathologist) saw under a high-powered microscope. While the language can be dense, the report is essentially a map that tells your care team whether the growths are completely benign, “atypical,” or something more serious [1][2].
The Microscopic View: What Makes a Papilloma?
To a pathologist, a papilloma is a specific structural growth. They look for three main components to confirm the diagnosis:
- Papillary Architecture: This refers to the “finger-like” or “frond-like” shape of the growth [3].
- Fibrovascular Cores: These are the “skeletons” of the fingers. They are made of connective tissue and blood vessels that provide support and nutrients to the growing cells [1][4].
- Two-Layered Lining: A healthy papilloma is lined by two distinct types of cells: luminal epithelial cells lining the inner surface facing the duct, and myoepithelial cells forming the outer/abluminal layer underneath [3][5].
The Role of Myoepithelial Cells
The presence of myoepithelial cells helps define the architecture. In many types of invasive breast cancer, this outer layer of cells disappears or becomes broken.
To see these cells more clearly, pathologists often use special “tags” called myoepithelial markers (such as p63, p40, or calponin). However, these immunostains are not a definitive “safety barrier.” They support the pathologist’s interpretation but must be read with the cell morphology. In-situ lesions (like DCIS) may retain myoepithelial cells, and no marker by itself excludes carcinoma [6][7]. A breast pathologist integrates the architecture, cytology, and imaging context together.
Understanding the “Spectrum” of Results
Pathology is not always a simple “yes or no” answer. Instead, it is a spectrum of how the cells look and behave.
1. Papilloma Without Atypia (Benign)
This means the cells are growing in a mass, but they look like normal, healthy breast cells. This is a completely benign result [1].
2. Papilloma With Atypia (High-Risk Lesion)
“Atypia” means some of the cells have started to look unusual or “monotonous” [8].
- Atypical ductal hyperplasia (ADH) is a common form of atypia. ADH is not cancer, but it is considered a “high-risk” finding because it is associated with a higher likelihood of an adjacent or future breast cancer [9][10].
- Atypia may be found within the papilloma itself or in the adjacent breast tissue.
3. Ductal Carcinoma In Situ (DCIS)
If the unusual cells meet defined cytologic and architectural features, it is classified as DCIS. While DCIS is non-invasive (the malignant cells remain confined to ducts and have not invaded surrounding tissue), it is a cancer diagnosis and requires a distinct treatment plan [9][11].
No “Stage” or “Grade” for Benign Papillomatosis
If your diagnosis is benign intraductal papillomatosis or papilloma with ADH, you will notice that your report does not include a stage (like Stage 1 or 2) or a grade (like Grade 1, 2, or 3).
- Staging is used only for cancer to describe how far it has spread [12].
- Grading describes how aggressive cancer cells look under a microscope [13].
Because benign papillomas and ADH are not cancer, these systems do not apply [14].
Pathology Report Checklist
When reviewing your report, ensure these key elements are addressed. If they aren’t, it’s a good reason to ask your doctor for more information.
- [ ] Exact Diagnosis: Does it explicitly state “without atypia” or name a specific high-risk lesion like ADH?
- [ ] Type of Procedure: Was this a core needle biopsy, a vacuum-assisted biopsy, or a surgical excision?
- [ ] Calcifications: If the biopsy was for microcalcifications, does the report state that calcium was present in the tissue?
- [ ] Surrounding Tissue: Does the report describe the health of the breast tissue around the papilloma? [15]
- [ ] Concordance (For the Radiologist): Ask your breast team if the radiologist formally determined that the pathology matches the imaging. (This is usually not printed on the lab report itself) [16].
Common questions in this guide
What does a benign papilloma without atypia mean on a breast pathology report?
Is atypical ductal hyperplasia inside a papilloma cancer?
What does DCIS mean when it appears with breast papillomatosis?
Why does my pathology report mention myoepithelial cells or p63 and p40?
Should a benign papillomatosis pathology report include a cancer stage or grade?
How can I tell whether my needle biopsy matches the breast imaging?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on intraductal breast papillomatosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my report mention 'usual ductal hyperplasia' or 'atypical ductal hyperplasia'?
- 2.If the biopsy was done for microcalcifications, does the report state that calcifications were present in the sample?
- 3.If atypia was found, was it located inside the papilloma itself or in the surrounding tissue?
- 4.Given that this was a needle biopsy, how confident are you that the sample represents the entire area seen on imaging?
- 5.Are there any terms in the report (like 'arborizing' or 'epithelial proliferation') that I need explained in more detail?
References
References (16)
- 1
Papillary Neoplasms of the Breast: WHO Classification, Multimodality Imaging, and Radiologic-Pathologic Correlation.
Thai JN, Vickery J, Boyraz B, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(8)):e240091 doi:10.1148/rg.240091.
PMID: 40674246 - 2
Pathological criteria and practical issues in papillary lesions of the breast - a review.
Ni YB, Tse GM
Histopathology 2016; (68(1)):22-32 doi:10.1111/his.12866.
PMID: 26768027 - 3
Classical Lobular Carcinoma In Situ Arising From an Intraductal Papilloma of the Breast: A Case Report.
Kim NI, Park MH, Lee JS
International journal of surgical pathology 2021; (29(5)):534-537 doi:10.1177/1066896920985216.
PMID: 33403884 - 4
Clinicopathologic features of intraductal papillary neoplasm of breast: analyses of three cases.
Zhao Y, Li N, Gong X, et al.
International journal of clinical and experimental pathology 2017; (10(9)):9575-9582.
PMID: 31966834 - 5
Spectrum of Papillary Breast Lesions According to World Health Organization Classification of Papillary Neoplasms of Breast.
Hashmi AA, Faraz M, Rafique S, et al.
Cureus 2020; (12(10)):e11026 doi:10.7759/cureus.11026.
PMID: 33214954 - 6
Encapsulated Papillary Carcinoma: A Case Report and Review of the Literature.
Athanasiou A, Khomsi F, de Joliniere B, Feki A
Frontiers in surgery 2021; (8()):743881 doi:10.3389/fsurg.2021.743881.
PMID: 35187043 - 7
Invasion in breast lesions: the role of the epithelial-stroma barrier.
Rakha EA, Miligy IM, Gorringe KL, et al.
Histopathology 2018; (72(7)):1075-1083 doi:10.1111/his.13446.
PMID: 29197112 - 8
Atypical Ductal Lesions of the Breast: Criteria, Significance, and Laboratory Updates.
East EG, Carter CS, Kleer CG
Archives of pathology & laboratory medicine 2018; (142(10)):1182-1185 doi:10.5858/arpa.2018-0221-RA.
PMID: 30281370 - 9
Ductal carcinoma in situ of the breast arising in a solitary intraductal papilloma.
Badrawi N, AlSayegh AA
Radiology case reports 2023; (18(2)):449-451 doi:10.1016/j.radcr.2022.11.014.
PMID: 36439917 - 10
Papillary lesions of the breast - review and practical issues.
Ni Y, Tse GM
Seminars in diagnostic pathology 2022; (39(5)):344-354 doi:10.1053/j.semdp.2022.06.001.
PMID: 35718581 - 11
Ductal Carcinoma in Situ: Current Concepts in Biology, Imaging, and Treatment.
Shehata M, Grimm L, Ballantyne N, et al.
Journal of breast imaging 2019; (1(3)):166-176 doi:10.1093/jbi/wbz039.
PMID: 31538141 - 12
Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
Doebar SC, van den Broek EC, Koppert LB, et al.
Breast cancer research and treatment 2016; (158(1)):179-187 doi:10.1007/s10549-016-3862-4.
PMID: 27318854 - 13
Atypia in breast pathology: what pathologists need to know.
Katayama A, Toss MS, Parkin M, et al.
Pathology 2022; (54(1)):20-31 doi:10.1016/j.pathol.2021.09.008.
PMID: 34872753 - 14
Use of fiberoductoscopy for the management of pathological nipple discharge: ten years follow up of a single center in China.
Zhang C, Li J, Jiang H, Li M
Gland surgery 2020; (9(6)):2035-2043 doi:10.21037/gs-20-738.
PMID: 33447554 - 15
Pathology of breast papillary neoplasms: Community hospital experience.
Vdovenko AA
Annals of diagnostic pathology 2020; (49()):151605 doi:10.1016/j.anndiagpath.2020.151605.
PMID: 32920473 - 16
Pathologic High-risk Lesions, Diagnosis and Management.
Murray M
Clinical obstetrics and gynecology 2016; (59(4)):727-732 doi:10.1097/GRF.0000000000000234.
PMID: 27681693
This page explains intraductal breast papillomatosis pathology terms for informational purposes only and does not constitute medical advice. Your pathologist and breast care team should interpret your report together with your imaging.